![Glenn Mattes](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Glenn Mattes
Chairman at
Cornovus Pharmaceuticals, Inc.
Profile
Glenn R.
Mattes is currently the Chairman at Cornovus Pharmaceuticals, Inc. since 2018.
He is also the Executive Chairman at Translational Sciences, Inc. since 2014, the Director at Viking Scientific, Inc. since 2016, the Director at CannaMetrix LLC since 2017, and the Operating Advisor at Revival Healthcare Capital LLC since 2018.
Previously, Mr. Mattes served as the President, CEO, Director & Head-Investor Relations at Arno Therapeutics, Inc. from 2011 to 2014.
He was also the President, Chief Executive Officer & Director at TFF Pharmaceuticals, Inc. from 2018 to 2022.
Additionally, he held positions as the President-Worldwide Commercial at Centocor, Inc. from 1998 to 2002, the General Manager-US Pharmaceuticals at Rhone Poulenc Rorer, and the President at Rhone-Poulenc Canada, Inc. He was the President at Tibotec Therapeutics, Inc. from 2003 to 2011.
Mr. Mattes obtained his undergraduate degree from City University of New York.
Glenn Mattes active positions
| Companies | Position | Start |
|---|---|---|
Cornovus Pharmaceuticals, Inc.
 Cornovus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and wholesales pharmaceutical products | Chairman | 2015-11-30 |
Revival Healthcare Capital LLC
 Revival Healthcare Capital LLC Investment ManagersFinance Revival Healthcare Capital invests in companies located in the United States with an enterprise value of USD 150 - 1000 million and revenue of USD 10 - 500 million. The firm targets companies operating in the fields of pharmaceuticals, biotech, drug development and discovery & healthcare services. It provides financing for buyout, recapitalization and growth stage capital requirements with an investment size of USD 10 - 250 million. The firm acquires majority, minority and controlling interest and makes co-investments. It also acts as a lead investor. | Consultant / Advisor | 2018-04-30 |
Translational Sciences, Inc.
 Translational Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Researches, develops and manufactures cardiovascular drugs | Chairman | 2014-11-30 |
CannaMetrix LLC | Director/Board Member | 2017-10-31 |
Viking Scientific, Inc.
 Viking Scientific, Inc. Pharmaceuticals: MajorHealth Technology Operates as preclinical stage drug delivery company, which develops next-generation controlled release products | Director/Board Member | 2016-09-30 |
Former positions of Glenn Mattes
| Companies | Position | End |
|---|---|---|
| TFF PHARMACEUTICALS, INC. | Chief Executive Officer | 2022-12-03 |
Deck Therapeutics, Inc.
 Deck Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an acute omega-3 fatty acid therapeutics development company | Director/Board Member | 2018-04-30 |
| ARNO THERAPEUTICS, INC. | Chief Executive Officer | 2014-07-17 |
Tibotec Therapeutics, Inc. | President | 2011-03-31 |
| ░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Training of Glenn Mattes
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
71
1st degree connections
15
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 15 |
|---|---|
Centocor, Inc.
 Centocor, Inc. Medical SpecialtiesHealth Technology Manufactures healthcare products | Health Technology |
Cornovus Pharmaceuticals, Inc.
Cornovus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and wholesales pharmaceutical products | Health Technology |
Rhone Poulenc Rorer
 Rhone Poulenc Rorer Chemicals: SpecialtyProcess Industries Manufactures and distributs pharmaceutical products. | Process Industries |
City University of New York
 City University of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Presidential Advisory Council on HIV/AIDS
 The Presidential Advisory Council on HIV/AIDS General GovernmentGovernment A government program | Government |
Arno Therapeutics, Inc.
 Arno Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on the clinical development of targeted cancer therapies and novel drug candidates for unmet medical needs | Health Technology |
Rhone-Poulenc Canada, Inc.
 Rhone-Poulenc Canada, Inc. Financial ConglomeratesFinance Part of Sanofi, Rhone-Poulenc Canada, Inc. is a Canadian company that operates in the banking industry. The company is based in Mississauga, Canada. | Finance |
Candel Therapeutics, Inc.
 Candel Therapeutics, Inc. BiotechnologyHealth Technology Develops and distributes immunotherapies for the treatment of cancer | Health Technology |
Viking Scientific, Inc.
Viking Scientific, Inc. Pharmaceuticals: MajorHealth Technology Operates as preclinical stage drug delivery company, which develops next-generation controlled release products | Health Technology |
TFF Pharmaceuticals, Inc.
 TFF Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures inhaled dry powder drugs for the treatment of pulmonary diseases and conditions | Health Technology |
Translational Sciences, Inc.
Translational Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Researches, develops and manufactures cardiovascular drugs | Commercial Services |
Revival Healthcare Capital LLC
Revival Healthcare Capital LLC Investment ManagersFinance Revival Healthcare Capital invests in companies located in the United States with an enterprise value of USD 150 - 1000 million and revenue of USD 10 - 500 million. The firm targets companies operating in the fields of pharmaceuticals, biotech, drug development and discovery & healthcare services. It provides financing for buyout, recapitalization and growth stage capital requirements with an investment size of USD 10 - 250 million. The firm acquires majority, minority and controlling interest and makes co-investments. It also acts as a lead investor. | Finance |
Tibotec Therapeutics, Inc. | |
CannaMetrix LLC | |
Deck Therapeutics, Inc.
Deck Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an acute omega-3 fatty acid therapeutics development company | Health Technology |
- Stock Market
- Insiders
- Glenn Mattes
